ribavirin
antivir
compound
wide
use
hepat
c
viru
therapi
biotransform
nucleosid
analogu
use
escherichia
coli
atcc
biocatalyst
herein
report
reaction
paramet
microorgan
amount
substrat
ratio
temperatur
optim
reach
convers
yield
biocatalyst
stabil
enhanc
immobil
agaros
matrix
immobil
biocatalyst
abl
reus
h
could
store
month
without
activ
loss
batch
packedb
reactor
base
stabil
biocatalyst
assay
bioprocess
scaleup
continu
sustain
bioprocess
evalu
use
prototyp
packedb
reactor
allow
produc
mg
ribavirin
final
work
effici
green
bioprocess
ribavirin
bioproduct
use
stabil
biocatalyst
develop
ar
ja
trell
nucleosid
analogu
polyfunct
molecul
includ
larg
famili
natur
modifi
compound
structur
divers
wide
spectrum
biolog
activ
molecul
use
power
antivir
antitumor
agent
ribavirin
guanosin
analogu
use
antivir
compound
hepat
c
viru
hcv
treatment
combin
peg
interferon
pegifn
furthermor
evalu
sever
acut
respiratori
syndrom
sar
anticanc
drug
success
result
treatment
leukemia
breast
cancer
last
year
pharmaceut
interest
molecul
increas
even
use
hcv
tripl
therapi
use
telaprevir
promis
result
patient
diagnosi
resist
convent
therapi
green
bioprocess
biocatalyt
reaction
recogn
superior
convent
chemic
method
select
modif
polyfunct
substrat
owe
high
catalyt
effici
inher
select
simpl
downstream
process
addit
biotransform
take
place
mild
condit
offer
environment
clean
technolog
abovement
nucleosid
analogu
biosynthes
modifi
convent
molecul
transglycosyl
reaction
use
nucleosid
phosphorylas
np
enzym
catalyz
revers
phosphorolyt
cleavag
nglycosid
bond
nucleosid
mechan
give
deoxyribos
second
step
mechan
phosphat
substitut
base
give
whole
cell
provid
onepot
bioprocess
nucleosid
analogu
biotransform
mani
enzym
involv
improv
yield
cofactor
regener
carri
bioprocess
prepar
condit
microorgan
immobil
requir
stabil
biocatalyst
entrap
techniqu
wide
use
whole
cell
immobil
provid
bioprocess
scaleup
feasibl
biocatalyst
reusabl
high
oper
stabil
work
ribavirin
biotransform
obtain
use
escherichia
coli
atcc
biocatalyst
microorgan
stabil
immobil
packedb
reactor
develop
bioprocess
scaleup
therefor
environment
friendli
smooth
econom
methodolog
antihcv
compound
biotransform
herein
report
nucleosid
purchas
sigma
chem
e
coli
atcc
grown
h
cultur
media
contain
gl
meat
pepton
gl
yeast
extract
gl
nacl
ph
mesophil
microorgan
evalu
screen
assay
cultur
accord
optim
grown
condit
cell
harvest
centrifug
min
g
wash
sodium
phosphat
buffer
mm
ph
ribavirin
biotransform
carri
use
colonyform
unit
cfu
ml
reaction
media
contain
equimolar
concentr
mm
uridin
urd
tca
sodium
phosphat
buffer
mm
ph
reaction
perform
h
c
rpm
previous
report
differ
amount
microorgan
cfu
evalu
ribavirin
biotransform
reaction
carri
differ
reaction
time
ml
sodium
phosphat
buffer
mm
ph
contain
mm
urd
tca
c
rpm
ribavirin
bioconvers
evalu
differ
temperatur
c
reaction
perform
use
cfu
rpm
h
ml
sodium
phosphat
buffer
mm
ph
contain
mm
urd
tca
substrat
initi
molar
ratio
analysi
reaction
perform
differ
urd
tca
ratio
mm
mm
use
cfu
ml
sodium
phosphat
buffer
mm
ph
c
rpm
differ
reaction
time
ribavirin
biotransform
perform
c
use
cfu
differ
stage
microorgan
growth
lag
exponenti
stationari
phase
reaction
carri
h
ml
sodium
phosphat
buffer
mm
ph
contain
mm
urd
mm
tca
biocatalyst
stabil
matrix
select
e
coli
atcc
immobil
entrap
agar
gracilaria
wv
agar
gelidium
wv
agaros
wv
polyacrylamid
wv
describ
rivero
et
al
microorgan
releas
determin
optic
densiti
nm
use
uvvi
spectrophotomet
pg
instrument
limit
releas
percentag
calcul
differ
initi
final
amount
cell
reaction
medium
stabil
biocatalyst
test
ribavirin
biotransform
h
previous
optim
reaction
condit
mm
tca
mm
urd
sodium
phosphat
buffer
mm
ph
cfu
c
rpm
reusabl
stabil
biocatalyst
evalu
success
standard
ribavirin
biotransform
initi
activ
loss
matrix
integr
loss
moreov
storag
stabil
assay
keep
immobil
deriv
c
determin
activ
differ
time
previous
describ
reusabl
assay
batch
packedb
reactor
develop
increas
fivefold
optim
amount
select
stabil
biocatalyst
reaction
perform
ml
ml
buffer
sodium
phosphat
mm
ph
contain
mm
urd
mm
tca
batch
packedb
reactor
respect
biosynthet
reaction
carri
c
h
batch
reactor
stir
rpm
assay
use
orbit
shaker
ferca
argentina
packedb
reactor
constant
flow
mlmin
achiev
use
peristalt
pump
apema
pc
argentina
ribavirin
obtain
four
reaction
use
packedb
reactor
concentr
speedvac
avanti
franc
appli
tlc
separ
silica
gel
merk
germani
use
matrix
chloroform
glacial
acet
acid
methanol
mobil
phase
product
recov
scrape
adsorb
plate
pure
ribavirin
elut
use
methanol
solvent
ribavirin
purif
corrobor
hplc
ribavirin
qualit
analyz
tlc
silicagel
f
merck
germani
previous
describ
ribavirin
detect
use
thermochem
reaction
use
ethanol
panisaldehyd
glacial
acet
acid
sulfur
acid
pv
develop
solut
dri
tlc
heat
c
min
moreov
ribavirin
bioconvers
quantit
monitor
hplc
gilson
nm
detector
uvvi
gilson
use
phenomenex
luna
column
mm
mm
isocrat
mobil
phase
water
use
flow
mlmin
product
identif
perform
mshplc
mention
condit
ribavirin
use
thermo
finnigan
spectromet
electron
spray
ioniz
method
esi
one
ion
trap
detector
well
known
biocatalyst
abl
biosynthes
sever
nucleosid
analogu
thu
strain
correspond
microbi
genera
test
ribavirin
biotransform
scheme
six
strain
aeromona
erwinia
micrococcu
escherichia
genera
abl
produc
ribavirin
use
urd
tca
reagent
wide
known
enzym
involv
transglycosyl
reaction
purin
nucleosid
phosphorylas
pnp
ii
uridin
thymidin
phosphorylas
tp
present
escherichia
enterobact
bacillu
mani
genera
therefor
presenc
differ
kind
np
could
explain
result
obtain
use
distinct
microorgan
genera
addit
outer
membran
e
coli
relat
gramneg
bacteria
contain
nucleosidespecif
porin
facilit
entri
nucleosid
periplasm
space
import
across
inner
membran
brought
activ
transport
system
biochem
evid
suggest
presenc
nucleosid
transport
system
differ
affin
demonstr
microorgan
codifi
sever
abc
transport
e
coli
known
contain
one
activ
transport
system
nucleosid
uptak
therefor
differenti
biotransform
capabl
could
relat
abil
microorgan
differenti
intern
nucleosid
analogu
modif
natur
structur
among
evalu
strain
e
coli
atcc
show
highest
convers
rate
h
reaction
therefor
select
studi
optim
biocatalyst
amount
determin
paramet
improv
reaction
effici
therefor
differ
amount
microorgan
test
ribavirin
biotransform
reaction
perform
use
cfu
biocatalyt
activ
detect
first
hour
reaction
howev
increas
number
cell
cfu
show
higher
ribavirin
yield
shorter
reaction
time
even
though
higher
amount
biocatalyst
cfu
also
show
good
yield
fig
reaction
condit
select
subsequ
assay
due
reaction
revers
observ
h
well
oper
difficulti
alreadi
discuss
similar
biocatalyt
system
base
result
rise
amount
biocatalyst
decreas
reaction
time
consider
improv
ribavirin
biotransform
yield
select
amount
cell
subsequ
reaction
cfu
wide
known
whole
cell
use
biocatalyst
side
enzymat
activ
also
take
place
nucleosid
analogu
biotransform
differ
kind
enzym
deaminas
halogenas
among
best
known
report
enzym
interfer
reaction
interest
gener
subproduct
decreas
yield
situat
revers
assess
reaction
temperatur
desir
biotransform
furthermor
noteworthi
bacteri
np
retain
activ
wide
temperatur
rang
c
henc
optim
temperatur
select
use
whole
cell
biotransform
reaction
carri
c
although
ribavirin
bioconvers
detect
evalu
temperatur
signific
increas
achiev
reaction
perform
c
fig
first
time
ribavirin
biotransform
perform
c
therefor
abil
e
coli
atcc
work
temperatur
use
solubl
substrat
urd
allow
perform
assay
c
favor
bioprocess
scaleup
hand
differ
substrat
concentr
test
aforement
bioprocess
equimolar
ratio
assay
convers
yield
h
reaction
wherea
excess
ribos
donor
nucleosid
evalu
yield
simultan
observ
howev
signific
increas
ribavirin
bioconvers
h
use
excess
tca
achiev
almost
doubl
origin
reaction
rate
use
equimolar
condit
fig
well
known
transglycosyl
reaction
revers
previou
report
demonstr
use
excess
substrat
significantli
improv
convers
valu
case
base
excess
promot
second
reaction
step
scheme
shift
equilibrium
toward
product
take
avail
turn
ribavirin
biotransform
nucleosid
analogu
catalyz
np
involv
nucleosid
salvag
pathway
differenti
transcriptom
proteom
found
depend
microbi
growth
phase
cultur
nutrit
need
ground
differ
e
coli
atcc
growth
phase
assay
ribavirin
biotransform
microorgan
stationari
phase
h
assay
reaction
yield
around
howev
microorgan
exponenti
phase
h
evalu
ribavirin
biotransform
yield
lower
observ
howev
cultur
reach
earli
stationari
phase
h
convers
yield
rais
statist
data
analysi
duncan
test
demonstr
best
condit
h
cultur
h
signific
chang
observ
fig
differenti
behavior
may
relat
np
express
due
nucleosid
salvag
pathway
activ
work
improv
yield
mark
reduct
reaction
time
ribavirin
bioconvers
achiev
allow
signific
increas
biotransform
product
differ
thermogel
gracilaria
granul
agar
agaros
test
matric
e
coli
atcc
stabil
accord
duncan
test
data
media
comparison
signific
differ
among
treatment
name
differ
letter
pvalu
observ
reaction
perform
three
time
bioconvers
rate
calcul
mmol
productmmol
limit
reagent
biocatalyst
immobil
agar
show
inappropri
cell
retent
therefor
biocatalyst
immobil
agaros
evalu
ribavirin
biotransform
obtain
yield
e
coli
atcc
immobil
synthet
polym
polyacrylamid
cell
releas
observ
biocatalyst
abl
yield
ribavirin
henc
agaros
polyacrylamid
select
success
assay
stabil
biocatalyst
retain
activ
howev
polyacrylamid
matrix
turn
less
resist
agaros
matrix
integr
loss
could
observ
h
bioprocess
moreov
biocatalyst
immobil
agaros
activ
h
without
signific
activ
loss
data
shown
biocatalyst
stabil
storag
condit
test
biocatalyst
immobil
agaros
stabl
day
biocatalyst
immobil
polyacrylamid
retain
activ
day
fig
regard
biocatalyst
stabil
immobil
consider
increas
therefor
effici
green
biotransform
use
wild
type
e
coli
atcc
achiev
without
need
appli
expens
techniqu
genet
engin
previous
report
fig
storag
stabil
assay
e
coli
immobil
agaros
wv
polyacrylamid
wv
reaction
perform
three
time
optim
condit
mm
tca
mm
urd
c
rpm
h
rel
activ
calcul
use
initi
condit
control
scaleup
bioprocess
ribavirin
biosynthesi
use
batch
packedb
reactor
environment
factor
calcul
previous
report
two
prototyp
assay
use
previous
optim
condit
stabl
immobil
biocatalyst
batch
packedb
reactor
develop
ribavirin
bioconvers
achiev
mg
compound
respect
ribavirin
almost
increas
twofold
packedb
reactor
evalu
kind
reactor
advantag
lower
shear
stress
immobil
biocatalyst
gener
lead
longterm
microorgan
stabil
packedb
reactor
common
econom
choic
largescal
chemic
product
manufactur
therefor
packedb
prototyp
evalu
ribavirin
biotransform
continu
bioprocess
h
allow
obtain
mg
product
green
chemic
paramet
aforement
bioprocess
calcul
demonstr
way
develop
abovement
prototyp
posit
affect
mass
util
effici
environmentalfactor
efactor
measur
industri
environment
impact
gener
valu
pharmaceut
compound
synthesi
around
present
work
efactor
valu
ribavirin
biotransform
lower
five
suggest
mass
util
effici
signific
decreas
wast
product
moreov
carbon
effici
ceffici
atom
economi
aeconomi
design
paramet
evalu
effici
synthet
reaction
ceffici
valu
near
aeconomi
valu
ribavirin
bioconvers
impli
posit
effect
atom
recoveri
process
effici
tabl
purif
molecul
prepar
tlc
previous
describ
work
sever
solvent
ratio
differ
polar
evalu
ribavirin
purif
retard
factor
rf
ribavirin
close
differ
substrat
urd
use
bioprocess
allow
recov
silica
gel
fraction
product
interest
therefor
natur
nucleosid
load
contigu
line
obtain
ribavirin
refer
purif
techniqu
allow
obtain
mg
purifi
ribavirin
without
presenc
substrat
secondari
product
see
supplementari
data
develop
easi
rapid
method
purif
allow
obtain
pure
ribavirin
micro
scale
subsequ
biocatalyt
modif
evalu
activ
vitro
e
coli
atcc
select
best
strain
biotransform
ribavirin
compound
wide
use
antihcv
treatment
reaction
paramet
optim
improv
convers
rate
decreas
reaction
time
biocatalyst
immobil
allow
stabil
reutil
bioprocess
scaleup
promis
result
use
low
temperatur
environment
friendli
reaction
condit
